Alvotech and Teva Pharmaceuticals have received approval from the Food and Drug Administration for Selarsdi (ustekinumab-aekn) injection as a biosimilar to Janssen's Stelara.
Designed for subcutaneous use, it is used for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of Selarsdi in the United States.
drugstorenews.com
Designed for subcutaneous use, it is used for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of Selarsdi in the United States.
Teva, Alvotech obtain FDA OK for Stelara biosimilar
Selarsdi (ustekinumab-aekn) injection for subcutaneous use is for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis.
drugstorenews.com
